Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions.

Laurianne Van Landeghem, Maxime Mahé, Raluca Teusan, Jean Léger, Isabelle Guisle, Rémi Houlgatte, Michel Neunlist

To cite this version:
Laurianne Van Landeghem, Maxime Mahé, Raluca Teusan, Jean Léger, Isabelle Guisle, et al.. Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions.. BMC Genomics, BioMed Central, 2009, 10 (1), pp.507. 10.1186/1471-2164-10-507.

HAL Id: inserm-00663570
https://www.hal.inserm.fr/inserm-00663570
Submitted on 27 Jan 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Regulation of intestinal epithelial cells transcriptome by enteric glial cells: impact on intestinal epithelial barrier functions

Laurianne Van Landeghem1,2,3, Maxime M Mahé1,2,3, Raluca Teusan2,4, Jean Léger2,4, Isabelle Guisle2,4, Rémi Houlgatte2,4,5 and Michel Neunlist*1,2,3

Address: 1INSERM, U913, Nantes, F-44000 France, 2Université de Nantes, Faculté de Médecine, Nantes, F-44000 France, 3CHU Nantes, Institut des Maladies de l’Appareil Digestif, Nantes, F-44000 France, 4INSERM, U915, Institut du Thorax, Nantes, F-44000 France and 5CHU Nantes, Institut du Thorax, Nantes, F-44000 France

Email: Laurianne Van Landeghem - laurianne.van-landeghem@univ-nantes.fr; Maxime M Mahé - maxime.mahe@univ-nantes.fr; Raluca Teusan - raluca.teusan@nantes.inserm.fr; Jean Léger - jean.leger@nantes.inserm.fr; Isabelle Guisle - isabelle.guisle@nantes.inserm.fr; Rémi Houlgatte - remi.houlgatte@nantes.inserm.fr; Michel Neunlist* - michel.neunlist@univ-nantes.fr

* Corresponding author

Abstract

Background: Emerging evidences suggest that enteric glial cells (EGC), a major constituent of the enteric nervous system (ENS), are key regulators of intestinal epithelial barrier (IEB) functions. Indeed EGC inhibit intestinal epithelial cells (IEC) proliferation and increase IEB paracellular permeability. However, the role of EGC on other important barrier functions and the signalling pathways involved in their effects are currently unknown. To achieve this goal, we aimed at identifying the impact of EGC upon IEC transcriptome by performing microarray studies.

Results: EGC induced significant changes in gene expression profiling of proliferating IEC after 24 hours of co-culture. 116 genes were identified as differentially expressed (70 up-regulated and 46 down-regulated) in IEC cultured with EGC compared to IEC cultured alone. By performing functional analysis of the 116 identified genes using Ingenuity Pathway Analysis, we showed that EGC induced a significant regulation of genes favoring both cell-to-cell and cell-to-matrix adhesion as well as cell differentiation. Consistently, functional studies showed that EGC induced a significant increase in cell adhesion. EGC also regulated genes involved in cell motility towards an enhancement of cell motility. In addition, EGC profoundly modulated expression of genes involved in cell proliferation and cell survival, although no clear functional trend could be identified. Finally, important genes involved in lipid and protein metabolism of epithelial cells were shown to be differentially regulated by EGC.

Conclusion: This study reinforces the emerging concept that EGC have major protective effects upon the IEB. EGC have a profound impact upon IEC transcriptome and induce a shift in IEC phenotype towards increased cell adhesion and cell differentiation. This concept needs to be further validated under both physiological and pathophysiological conditions.
Background
The intestinal epithelial barrier (IEB) is the first boundary between the organism and the luminal environment. It plays a dual role by allowing the passage of nutrients and electrolytes but preventing the passage of pathogens. The maintenance of its homeostasis is of utmost importance for the survival of the organism. The IEB is formed by a monolayer of specialized intestinal epithelial cells (IEC) under constant renewal and maintained together via various cell-to-cell and cell-to-matrix interactions. The IEB is part of a complex network of specialized cell types constituting its microenvironment such as immune cells, subepithelial fibroblasts, endothelial cells or luminal bacteria. Emerging evidences suggest that under physiological conditions, the IEB's functions are actively regulated by its cellular microenvironment [1-3]. For instance, myofibroblasts have been shown to enhance epithelial cell proliferation and intestinal epithelial restitution [4]. In addition, microbiota have been shown to control both the maturation and the maintenance of the IEB [5].

The enteric nervous system (ENS) is also a major constituent of the cellular microenvironment of the IEB. Indeed IEB and, in particular, the proliferative compartment of the crypts are densely innervated by nerve fibres originating mainly from the submucosal plexus. Recent data have shown that, besides controlling secretory processes, activation of enteric neurons can reduce IEC proliferation and barrier permeability, in particular via the release of vasoactive intestinal peptide (VIP) [6-8]. Enteric neurons innervating the IEB are also closely associated with enteric glial cells (EGC), the major constituent of the ENS.

For many years, EGC have been considered as mainly passive and structural cells supporting neurons and ganglia. However, this concept has lately been revisited mainly focused on the role played by astrocytes in the central nervous system (CNS) [9-11]. Besides controlling and regulating neuronal functions, increasing evidence suggests that EGC could be major regulators of IEB functions, similar to astrocytes controlling blood brain barrier functions [10]. Supporting this concept, recent data have demonstrated that EGC can profoundly inhibit IEC proliferation, in part via the liberation of TGF-β1 [12]. EGC also decrease IEB paracellular permeability via the release of S-nitrosoglutathione (GSNO) [13]. Furthermore, in vivo lesions of EGC network increase IEB paracellular permeability and IEC proliferation and, at term, lead to major lethal intestinal inflammation [13-15]. However, the role of EGC in the control of other major IEC functions such as cell differentiation, cell-to-cell or cell-to-matrix adhesion, and the associated regulatory pathways remains largely unknown.

Therefore, in our study, we combined transcriptomic studies as well as functional studies to determine the impact of EGC on the regulation of major genes and functions involved in IEB homeostasis. Microarray approach was used to identify EGC-induced modifications in gene expression profiling of proliferating Caco-2. The identified genes and related functional pathways are consistent with the concept that EGC are a major constituent of the IEB microenvironment favoring barrier protection.

Results and Discussion
Enteric glial cells modulate intestinal epithelial cells transcriptome
Microarray experiments
We performed microarray analysis of EGC influence on the transcriptome of Caco-2 cells using oligonucleotide chips (Cancerochips) developed at West Genopole transcriptome core facility of Nantes. These microarrays contain around 6,864 genes and are dedicated to gene expression studies in Caco-2 cell line as well as to gene expression signature studies of multiple tumors. Caco-2 cells were cultured onto Transwell filters in the absence or presence of EGC seeded at the bottom of the wells for 8 or 24 hours. The Transwell filters did not allow any contact between IEC and EGC, thus implicating only paracrine communication between the two cell types.

Hierarchical clustering of the whole data showed the impact of the time of culture as well as the impact of the presence of EGC on the transcriptional profiling of IEC, i.e. Caco-2 cells (Figure 1). We observed changes in IEC transcriptome over the 24 hours of culture in control condition. At 8 hours, differences in transcriptome profiling already existed in control condition as compared to t = 0. In general, the observed changes in differentially expressed genes between t = 0 and t = 8 hours in control conditions were increased in the same way of regulation when reaching t = 24 hours (Figure 1). These changes might be due to the growth and differentiation of the proliferating IEC over the 24 hours of culture. We observed no major differences in gene expression profiling between IEC cultured alone and IEC cultured in presence of EGC at 8 hours of culture. In contrast, at 24 hours, EGC presence led to consistent and major changes in IEC gene expression profiling (Figure 1).

Gene expression modulated by EGC
Using Genespring software, we aimed to identify statistically significant differences in gene expression profiling between Caco-2 cells cultured alone or in presence of EGC. After 8 h of culture, no significant difference in gene expression profiling was found between IEC cultured alone (control condition) or in presence of EGC ("glia" condition). However, after 24 hours of culture, we identified 116 genes differentially expressed between control
Figure 1
Hierarchical clustering of expression data. Four individual microarrays were used per condition. Hierarchical clustering was performed on genes using Gene Cluster. Each ratio was normalized to the median of the t = 0 hour-condition values of the corresponding gene. Each column represents an individual array (T0: t = 0 hour condition samples; T8control: t = 8 hours of culture without EGC; T8glia: t = 8 hours of culture in presence of EGC; T24control: t = 24 hours of culture without EGC; T24glia: t = 24 hours of culture in presence of EGC). Each line represents one individual gene. The clustering shows the impact of the time of culture on gene expression profiling in Caco-2 cells. The EGC-induced modulation of IEC transcriptome is highly visible at t = 24 hours.
and EGC conditions by using two different strategies. Ben-
jamin and Hochberg False Discovery Rate method was
used to determine 98 differentially expressed genes
between control and glia conditions at t = 24 hours, and
we also selected 27 genes with a two-fold change and Stu-
dent’s t-test p-value less than or equal to 0.05. Among the
116 differentially expressed genes, 46 genes were down-
regulated and 70 were up-regulated in IEC cultured with
EGC as compared to control (Table 1, 2). Quantitative
PCR was also performed on various genes to validate the
microarray results. In particular, results showed an EGC-
induced increase of CDH1, FN1, LAMA5, PPARG, PTK2
mRNA expression in IEC and a decrease of E2F1, FGFR2,
GPX2 and SMAD3 mRNA expression in IEC, similar to the
data obtained with microarrays (Figure 2A). We next
sought to determine the specificity of EGC effects upon
IEC transcriptome by characterizing the impact of fibro-
blasts on the expression of these genes in IEC. Under iden-
tical culture conditions, we showed that fibroblasts
increased expression of PTK2 but did not significantly
modify gene expression of CDH1, FN1, LAMA5, PPARG,
E2F1, GPX2 and SMAD3 in IEC (Figure 2B).

Hierarchical clustering of differentially expressed genes
Hierarchical clustering was used to visualize the expres-
sion profile of the 116 genes induced or repressed by EGC
after 24 hours of culture (Figure 3).

All these genes exhibit a differential expression between
control and EGC conditions at t = 24 hours. Furthermore,
some of them already exhibited a slight difference in
expression profile between control and EGC conditions at
8 hours. These results indicate that EGC effects on genes
identified as differentially expressed in IEC at 24 hours
probably started as early as at 8 hours, even though the
modifications were not statistically significant.

Two groups of samples exhibited a very different profile
from other samples: EGC condition at t = 24 hours and
controls at t = 24 hours (Figure 3). These observations
confirm that 1) no major changes existed between control
and EGC conditions at t = 8 hours and 2) that the 24 hour-
technical culture impacted on gene expression profi-
ing EIC, likely reflecting differentiation of IEC over the time of
culture.

EGC regulate IEC functions

Gene network interactions
Biological interactions among the 116 genes of the gene
set provided by Genespring analysis were identified using
Ingenuity Pathways Analysis. Among the 116 genes dif-
ferentially expressed, Ingenuity identified 92 genes con-
tributing to a total of 10 functional networks (Table 3). Each
of the 6 first networks contained at least 14 genes that
were associated with cell-to-cell signalling and interac-
tion, cellular growth and proliferation, cell morphology,
cellular movement, cell death and cell cycle. The 116
genes were also classified into Ingenuity cellular and
molecular pathways as well as into Ingenuity signalling
pathways (Table 4 and 5). All the functions described
above and identified by building functional networks
among our gene set were found in the 25 cellular and
molecular functions obtained with Ingenuity (Table 4).
Moreover, these 6 functions were among the 10 first func-
tions presenting the highest score (Table 4). Finally, the
signalling pathways identified by the Ingenuity analysis of
our gene set were also relevant to those 6 functions (Table
5). The limit of Ingenuity analysis for our study is that it is
not restricted to one specific organ or cell, so that all the
results of Ingenuity analysis could not be transposed
directly to the regulation of IEC functions by EGC. We
therefore performed an "epithelial" specific analysis of the
major functions identified with Ingenuity.

Cell-to cell and cell-to-matrix interaction
EGC regulated the expression of numerous genes involved
in the control of IEC adhesive processes. In particular,
EGC induced an up-regulation of the expression of all 7
genes with pro-adhesive functions and a down-regulation
of the 2 genes with anti adhesive properties, among the
gene set found to be differentially expressed in IEC cul-
tured in presence of EGC (Table 6). These genes are cru-
ially involved in the control of cell-to-cell and cell-to-
matrix adhesion.

First, EGC concomitantly increased the expression of
CDH-1, which encodes E-cadherin, and decreased the
expression of CDK5R1. E-Cadherin is the major compo-
nent of the adherent junction complexes and the level of
E-Cadherin in IEC is to be correlated to adhesion com-
plexes formation between IEC [16,17]. Further evidences
confirming a pro-adhesive influence of EGC on IEC is the
EGC-induced down-regulation of CDK5R1 expression.
Indeed, CDK5R1 encodes p35, a regulator of CDK-5 (cy-
clin-dependent kinase), which induces the degradation of
E-Cadherin precursor [18]. In addition, EGC also up-regu-
lated IQGAP2 expression in IEC. This gene encodes for a
protein member of IQGAP family that interacts with sev-
eral molecules controlling cytoskeleton organization, cell
adhesion and cell motility such as CDC42 and Rac [19].
Interestingly, IQGAP2 has been shown to mediate E-Cad-
herin-based cell-to-cell adhesion during development
[20]. All these results suggest that EGC enhance cell-to-cell
adhesion in IEC.

Our data also demonstrate that EGC modulate the expres-
sion of genes that are involved in cell-to-matrix interac-
tions. First, EGC increased expression of several genes
encoding proteins of the extracellular matrix such as
LAMA5, LAMC1 and FN1. LAMA5 and LAMC1 encode
Table 1: List of the genes up-regulated by enteric glial cells in intestinal epithelial cells.

| Gene Symbol | Genbank   | Description                                                                 | % up-regulation (control) | Fold difference |
|-------------|-----------|-----------------------------------------------------------------------------|---------------------------|-----------------|
| TXNIP       | NM_006472 | thioredoxin interacting protein                                              | 217.60                    | 3.18            |
| ANKRD1      | NM_014931 | ankyrin repeat domain 1 (cardiac muscle)                                    | 169.22                    | 2.69            |
| FNI         | U42593    | fibronectin 1                                                                | 152.16                    | 2.52            |
| TUBB3       | NM_006066 | tubulin, beta 3                                                              | 149.94                    | 2.50            |
| MGML        | A1270950  | monoglyceride lipase                                                          | 135.97                    | 2.36            |
| METTL7A     | NM_014033 | methyltransferase like 7A                                                    | 132.96                    | 2.33            |
| PKN2        | NM_006356 | protein kinase N2                                                             | 128.33                    | 2.28            |
| /           | XM_166201 | synonyms: KIAA0056, MGC104671; Homo sapiens KIAA0056 protein (hCAP-D3), mRNA. | 115.09                    | 2.15            |
| EPB41L2     | NM_001431 | erythrocyte membrane protein band 4.1-like 2                                | 110.50                    | 2.11            |
| AASS        | AI007714  | aminoadipate-semialdehyde synthase                                           | 110.15                    | 2.10            |
| ACTG2       | NM_001615 | actin, gamma 2, smooth muscle, enteric                                        | 102.56                    | 2.03            |
| B4GALT5     | NM_004776 | UDP-Gal:betaGlcNac beta 1,4-galactosyltransferase, polypeptide 5             | 102.38                    | 2.02            |
| /           | /         | Homo sapiens cDNA clone IMAGE:4690793, with apparent retained intron.        | 101.66                    | 2.02            |
| KRT8        | NM_002273 | keratin 8                                                                    | 81.96                     | 1.82            |
| SAT1        | NM_002970 | spermidine/spermine N1-acetyltransferase 1                                   | 80.24                     | 1.80            |
| ASS1        | NM_000050 | argininosuccinate synthetase                                                 | 76.73                     | 1.77            |
| S100A1IIP   | NM_021039 | /                                                                            | 75.22                     | 1.75            |
| SLC7A7      | NM_003988 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 7 | 72.31                     | 1.72            |
| HAGH        | NM_005326 | hydroxyacylglutathione hydrolase                                              | 69.54                     | 1.70            |
| BNP3L       | AF536326  | BCL2/adenovirus E1B 19 kDa interacting protein 3-like                        | 69.19                     | 1.69            |
| /           | /         | PRR5-ARHGAP8 fusion                                                          | 68.01                     | 1.68            |
| BNP3        | NM_004052 | BCL2/adenovirus E1B 19 kDa interacting protein 3                             | 67.84                     | 1.68            |
| IL18        | NM_001562 | interleukin 18 (interferon-gamma-inducing factor)                            | 67.14                     | 1.67            |
| RDM1        | BC038301  | RADS2 motif 1                                                                | 67.11                     | 1.67            |
| FAM107B     | NM_031453 | family with sequence similarity 107, member B                                | 65.70                     | 1.66            |
| PLAC8       | NM_016619 | placenta-specific 8                                                          | 63.77                     | 1.64            |
| SMARCA1     | NM_139033 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 | 63.72                     | 1.64            |
| PLAD2       | NM_009353 | procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2                          | 62.87                     | 1.63            |
| TMSBY4      | NM_004202 | thymosin, beta 4, Y-linked                                                   | 62.77                     | 1.63            |
| SCPEP1      | NM_021626 | serine carboxypeptidase 1                                                    | 60.96                     | 1.61            |
| LAM5        | NM_005560 | laminin, alpha 5                                                             | 60.53                     | 1.61            |
| LAMC1       | NM_002393 | laminin, gamma 1 (formerly LAMB2)                                           | 59.89                     | 1.60            |
| METAPI      | BC030054  | methionyl aminopeptidase 1                                                   | 59.55                     | 1.60            |
| IQGAP2      | NM_006633 | IQ motif containing GTPase activating protein 2                             | 58.98                     | 1.59            |
| C1orf43     | NM_015449 | chromosome 1 open reading frame 43                                         | 56.86                     | 1.57            |
| CASP4       | NM_001225 | caspase 4, apoptosis-related cysteine peptidase                              | 55.71                     | 1.56            |
| BTG1        | NM_001731 | B-cell translocation gene 1, anti-proliferative                              | 54.63                     | 1.55            |
| SLC2A1      | K03195    | solute carrier family 2 (facilitated glucose transporter), member 1         | 54.34                     | 1.54            |
| DCTN2       | NM_006400 | dynactin 2 (p50)                                                             | 52.68                     | 1.53            |
| TOP2A       | NM_001067 | topoisomerase (DNA) II alpha 170 kDa                                       | 52.42                     | 1.52            |
| KRT18       | NM_000224 | keratin 18                                                                   | 51.16                     | 1.51            |
| LAMC1       | M55210    | laminin, gamma 1 (formerly LAMB2)                                           | 50.37                     | 1.50            |
respectively for laminin α5 and γ1 chains which, together with laminin β1 chain, compose laminin-10 [21]. Laminin-10 has been shown to be the most adhesive substratum of laminin isoforms when studying abilities of laminin-2,-5 and -10 in modulating Caco-2 cell adhesion [22]. Furthermore, EGC up-regulated FN1 expression, encoding the fibronectin protein. Interestingly, fibronectin has recently been shown to enhance Caco-2 cell attachment and wound healing [23]. EGC down-regulated KLK14 expression, which encodes KLK (kallikrein) 14, an extracellular serine protease which has been shown to cleave and digest various extracellular matrix proteins such as collagen IV, laminin and fibronectin [24]. In addition, EGC up-regulated PTK2 expression in IEC which may result in increased expression of FAK (Focal Adhesion Kinase) protein, a major regulator of focal adhesions turnover and maturation [25]. Finally, EGC induced an up-regulation of KRT8 expression whose increased expression has recently been shown to cause enhanced adhesion of human breast tumor cells to their extracellular matrix [26].

In conclusion, our data suggest that EGC regulation of IEC transcriptome leads to an increase in cell adhesion. In order to functionally validate this hypothesis, we performed in vitro experiments using established adhesion assays. Under these conditions, we first showed that IEC global adhesion was increased after 24 hours of culture with EGC as compared to control (Figure 4A). We next confirmed whether these effects were in part associated with an increase in cell-to-matrix adhesion as the majority of IEC genes regulated by EGC presence appeared to favor cell-to-matrix adhesion. Indeed, cell-to-matrix adhesion assays revealed that EGC significantly increased IEC adhesion to the filter as compared to control (Figure 4B).

Cell differentiation
EGC also regulated the expression of numerous genes involved in IEC differentiation. In particular, EGC up-regulated the expression of 6 genes enhancing differentiation and down-regulated 3 genes known to inhibit IEC differentiation (Table 7).

EGC induced an up-regulation of the expression of pro-differentiative genes or genes associated with enhanced differentiation of IEC such as PPARγ, LAMA5, PTK2, CDH1, DCTN2 and DYNLT3. Indeed, PPARγ, encoding the well-described nuclear receptor superfamily member peroxisome proliferator-activated receptor gamma (PPAR-γ) has been shown to regulate IEC differentiation and its expression has been positively correlated with level of differentiation of Caco-2 and HT29 cells [27,28]. Moreover, a diminution of laminin-α5 in a murine model resulted in a transformation from a small intestinal to a colonic mucosal architecture, suggesting that laminin-α5 has a crucial role in establishing and maintaining the architecture of the small intestine [29]. In addition, it has already been shown that the differentiation of Caco-2

Table 1: List of the genes up-regulated by enteric glial cells in intestinal epithelial cells. (Continued)
cells was accompanied by an increase in FAK expression [30]. E-Cadherin, whose corresponding gene CDH-1 is up-regulated by EGC, has been largely demonstrated to be involved in the establishment of a differentiated phenotype for IEC. Notably, E-Cadherin has been described to be less expressed at the bottom of the crypts where IEC are

Table 2: List of the genes down-regulated by enteric glial cells in intestinal epithelial cells.

| Gene Symbol | Genbank       | Description                                                                 | % down-regulation (/control) | Fold difference |
|-------------|---------------|------------------------------------------------------------------------------|------------------------------|-----------------|
| CARD12      | AF376061      | caspase recruitment domain family, member 12                                | 83.43                        | 6.04            |
| KLRK1       | NM_022046     | kallikrein 14                                                                | 62.46                        | 2.66            |
| FGFR2       | NM_022970     | fibroblast growth factor receptor 2                                          | 57.12                        | 2.33            |
| BDP1        | NM_018429     | B double prime 1, subunit of RNA polymerase III                             | 56.58                        | 2.30            |
| SFRP4       | NM_003014     | secreted frizzled-related protein 4                                          | 55.26                        | 2.24            |
| C6          | NM_000065     | complement component 6                                                        | 54.78                        | 2.21            |
| PRKCD       | NM_006254     | protein kinase C, delta                                                      | 54.67                        | 2.21            |
|             | XM_066354     | Homo sapiens diacylglycerol kinase, kappa (DGKK), mRNA.                      | 54.24                        | 2.10            |
| C20orf33    | NM_01033086   | chromosome 20 open reading frame 133                                        | 52.36                        | 2.10            |
| PRKCO       | NM_006257     | protein kinase C, theta                                                      | 50.50                        | 2.02            |
| CDK5R1      | NM_003885     | cyclin-dependent kinase 5, regulatory subunit 1 (p35)                        | 50.42                        | 2.02            |
| RPP40       | NM_016638     | ribonuclease P 40 kDa subunit                                                | 47.41                        | 1.90            |
| SLC30A1     | AF225309      | solute carrier family 30 (zinc transporter), member 1                        | 46.22                        | 1.86            |
| TIMM8A      | NM_004085     | translocase of inner mitochondrial membrane B homolog A (yeast)              | 41.07                        | 1.70            |
| EBNA1Bp2    | NM_006824     | EBNA1 binding protein 2                                                       | 36.39                        | 1.57            |
| ITGAE       | NM_002208     | integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) | 36.17                        | 1.57            |
|             |               |                                                                              |                              |                 |
| NOL1        | NM_006170     | nucleolar protein 1, 120 kDa                                                 | 33.86                        | 1.51            |
| C6orf66     | NM_014165     | nucleolar protein 1, 120 kDa                                                 | 33.81                        | 1.51            |
| NOL5A       | NM_006392     | nucleolar protein 5A (56 kDa with KKE/D repeat)                             | 33.30                        | 1.50            |
| BAG1        | U46917        | BCL2-associated athanogene                                                    | 32.19                        | 1.47            |
|             | AF123354      | nucleolar protein NOP5/NOP58                                                  | 32.14                        | 1.47            |
| ASAH1       | AK025211      | N-aclysphingosine amidohydrolase (acid ceramidase) I                         | 29.98                        | 1.43            |
| TINAGLI     | AF23150       | tubulointestinal nephritis antigen-like 1                                    | 29.62                        | 1.42            |
| AADAC       | NM_001086     | arylacetamide deacetylase (esterase)                                        | 29.48                        | 1.42            |
| HSPA14      | AF112210      | heat shock 70 kDa protein 14                                                  | 29.34                        | 1.42            |
| PSMC6       | NM_002806     | proteasome (prosome, macropain) 26S subunit, ATPase, 6                      | 29.31                        | 1.41            |
| HNRPD1      | D89678        | heterogeneous nuclear ribonucleoprotein D-like                               | 28.40                        | 1.40            |
| SAMHD1      | NM_015474     | SAM domain and HD domain 1                                                    | 28.12                        | 1.39            |
| TPS3R       | NM_033550     | TPS3 regulating kinase                                                        | 26.93                        | 1.38            |
| MARK2       | NM_004954     | MAP/microtubule affinity-regulating kinase 2                                 | 26.41                        | 1.36            |
| CCR9        | NM_013200     | chemokine (C-C motif) receptor 9                                              | 24.74                        | 1.35            |
| RGL1        | NM_015149     | ral guanine nucleotide dissociation stimulator-like 1                        | 24.20                        | 1.32            |
| E2F1        | NM_005225     | E2F transcription factor 1                                                   | 23.90                        | 1.31            |
| PSMC1       | NM_002802     | proteasome (prosome, macropain) 26S subunit, ATPase, 1                      | 23.75                        | 1.31            |
| IMP3        | NM_018285     |IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast)                  | 23.48                        | 1.31            |
| RNU3IP2     | BC023662      | RNA, U3 small nucleolar interacting protein 2                                | 23.41                        | 1.31            |
| SMAD3       | NM_005902     | SMAD, mothers against DPP homolog 3 (Drosophila)                             | 22.49                        | 1.27            |
| GPX2        | NM_002083     | glutathione peroxidase 2 (gastrointestinal)                                  | 21.27                        | 1.27            |
| LSP1        | NM_002339     | lymphocyte-specific protein 1                                                | 21.21                        | 1.27            |
| FGG         | NM_021870     | fibrinogen gamma chain                                                       | 18.37                        | 1.23            |
| C20orf94    | NM_01009608   | chromosome 20 open reading frame 94                                          | 16.04                        | 1.19            |
| PPL1        | NM_016059     | peptidylprolyl isomerase (cyclophilin)-like 1                                | 14.74                        | 1.17            |
| HOXB2       | NM_002145     | homeobox B2                                                                  | 13.91                        | 1.16            |
| APOH        | NM_000042     | apolipoprotein H (beta-2-glycoprotein I)                                    | 13.17                        | 1.15            |
| PRSS23      | NM_002173     | protease, serine, 23                                                         | 10.41                        | 1.12            |
| IARS2       | NM_018600     | isoleucine-tRNA synthetase 2, mitochondrial                                  | 10.02                        | 1.11            |
undifferentiated [16,31,32]. The down-regulation by EGC of CDK5R1 expression, leading to enhanced levels of E-Cadherin (see previous paragraph), might also further enhance EGC-induced cell differentiation. EGC also increased DCTN2 and DYNLT3 expression, two genes encoding a subunit of dynactin (p50 or dynamitin) and dynein light chain rp3, respectively. Both are involved in post-Golgi movement of vesicles towards apical surface of differentiated enterocytes [33-35], and could therefore reflect increased differentiation of IEC induced by EGC.

Intriguingly, although differentiation of the Caco-2 cell line has been shown to be correlated with a down-regulation in fibronectin expression [36], EGC induced an up-regulation in FN1 expression in IEC in our study.

EGC decreased the expression of genes that encode proteins implicated in anti-differentiative pathways such as E2F1, BAG1 and CDK5R1 (discussed above). E2F1 is a gene encoding a protein member of the E2F family of transcription factors and has been shown to be down-regulated in confluent human IEC and differentiated enterocytes [37]. BAG1, encoding a Bcl-2 non-homologous associated molecule, has also been shown to present a decreasing gradient of expression from the base of the crypts to the apex of the villi, suggesting that the down-regulation of BAG1 might reflect a differentiation state of IEC [38].

In conclusion, based on our analysis, EGC-mediated regulation of IEC transcriptome appears to strongly favor IEC differentiation.

**Cell motility**

EGC regulated in IEC the expression of genes encoding proteins that are known to play a role in IEC motility (Table 8). In particular, EGC induced an increase in FN1 expression in IEC. FN1 has been demonstrated as a major factor in promoting cell migration of IEC and subepithelial fibroblasts, thus favoring epithelial wound healing [39,40]. Interestingly, EGC induced a down-regulation in LSP1 expression in IEC. LSP1 gene encodes for LSP1, a cytoplasmic actin-binding protein, whose overexpression in melanoma cells has been described to inhibit cell motility [41]. EGC-induced up-regulation of PTK2 expression also supports a role of EGC in promoting IEC motility. Indeed, increased FAK protein level promoted epithelial restitution via an increased IEC migration [42,43]. Similarly, the increased PPARγ expression could...
Hierarchical clustering of the 116 identified genes expression data. Four individual microarrays were used per condition. Hierarchical clustering was performed on conditions and on the 116 genes identified with Genespring. Each ratio was normalized to the median of the t = 0 hour-condition values of the corresponding gene. Each column represents an individual array (T0: t = 0 hour condition samples; T8control: t = 8 hours of culture without EGC; T8glia: t = 8 hours of culture in presence of EGC; T24control: t = 24 hours of culture without EGC; T24glia: t = 24 hours of culture in presence of EGC). Each line represents one individual gene. The clustering reveals clusters of genes with similar pattern of expression among the different conditions. The cluster also shows the distance between the five conditions demonstrating major changes induced by the culture with EGC at t = 24 hours.
enhance cell motility as inhibitors of PPARγ inhibit epithelial cell migration [44-46].

**Cell proliferation**

Expression of genes involved in cell proliferation was differentially regulated in IEC cultured in presence of EGC as compared to control (Table 9). In fact, EGC appeared to modulate the expression of anti-proliferative and pro-proliferative genes toward a dominant anti-proliferative effect (Table 9).

The expression of major anti-proliferative and pro-proliferative genes was found to be up-regulated and down-regulated, respectively, by EGC. In particular, PPARγ, TXNIP and BTG1 expressions in IEC were up-regulated by EGC. PPARγ activation has been described both in vivo and in vitro to inhibit intestinal epithelial cell proliferation [47,48] and to induce a G1 phase cell cycle arrest [27]. Furthermore, TXNIP encodes the thioredoxin-interacting protein, a negative regulator of thioredoxin. Thioredoxin is an important growth-promoting factor of IEC [49]. Moreover, TXNIP has also recently been suggested to be a tumor suppressor gene in hepatocellular carcinoma [50] and interestingly, TXNIP expression is decreased in colorectal cancer and ulcerative colitis [51]. Similarly, BTG1 has been shown to negatively regulate cell proliferation and to present a maximal expression during G0/G1 phases of the cell cycle in fibroblasts [52]. Further reinforcing the anti-proliferative effects of EGC on IEC is the EGC-induced down-regulation of the expression of pro-proliferative genes such as E2F1, FGFR2 and PPIL1. E2F1 is a gene encoding a protein member of the E2F family of transcription factors that regulate cell cycle progression by modulating expression of proteins required for the G1/S transition. It has been well described that growth stimulatory signals lead to active E2F1 accumulation and S-phase...
entry [53,54]. FGFR2 encodes a member of the FGF (Fibroblast Growth Factor) receptor family with high affinity for KGF (Keratinocyte Growth Factor) which is a major actor in the mesenchymal stimulation of epithelial cell proliferation [55,56]. Finally, PPIL1, which encodes a cyclophilin-related protein, PPIL1 (peptidyl prolyl isomerase-like protein), implicated in spliceosome activation, has recently been described to be overexpressed in colon tumors and PPIL1 silencing led to an inhibition of colon cancer cell growth [57,58].

These global anti-proliferative effects of EGC upon IEC have to be associated with the EGC-induced modulation of genes that would tend to be pro-proliferative, although these are clearly in reduced numbers. For instance, EGC increase MKI67 expression, which encodes the proliferation marker Ki-67. Indeed, Ki-67 is increasingly expressed during the cell cycle phases [59], excepted in G0 or in cells just escaping from G0 [60]. Its function is still unclear but knock-down for Ki-67 in cancerous cells leads to an inhibition of proliferation mainly via an induction of apoptosis [61,62]. Interestingly, EGC reduced the expression of TP53RK and SFRP4 in IEC that encode proteins involved in anti-proliferative pathways. TP53RK encodes PRPK which is a short kinase that phosphorylates p53, enhancing its transcriptional activity [63] and suppressing cell cycle transition G1/S [64]. SFRP4 encodes the protein sFRP4 (secreted frizzled-related protein), which is an inhibitor of the Wnt-signaling cascade through binding and sequestering Wnt ligand and, thus, has been shown to decrease cell proliferation in many cell lines [65-67].

### Table 4: Lists of differentially expressed genes involved in cellular and molecular functions regulated in intestinal epithelial cells by enteric glial cells.

| Ingenuity® cellular and molecular functions | Genes list | Score |
|---------------------------------------------|------------|-------|
| RNA Post-Transcriptional Modification | NOP5/NOP58, NOL5A, EBNA1BP2, RNU3IP2, IMP3 | 5.17 |
| Cell Death | GPX2, SAT, PRKCD, B4GALT5, CDH1, TXNIP, TOP2A, CDH1, PKN2, ASAH1, LPS1, BNI31, NPPB, CDKSR1, ANKRD1, VIP, CASP4, GLRX, FGGF2, KRT18, BAG1, PRKCC, BTG1, PPARG, C6orf66, SLC2A1, CARD12, SMAD3, FTH1, LAMAS, PTK2, IL18, MLLT3, FN1, PLAC8, KRT8, TGFBI, BNP3, E2F1, SFRP4 | 4.85 |
| Cell-To-Cell Signaling and Interaction | APOH, PRKCD, SMAD3, CDH1, PKN2, LAMAS, PTK2, VIP, IL18, FN1, FGFR2, KRT18, BAG1, ITGAE, LAMC1, PPARG, TGFBI, E2F1 | 3.92 |
| Cellular Development | SMAD3, PRKCD, CDH1, LAMAS, VIP, PTK2, IL18, CDKSR1, FGFR2, FN1, PLAC8, PRKCC, LAMC1, PPARG, E2F1 | 3.92 |
| Cell Morphology | SMAD3, PRKCD, CDH1, LAMAS, LPS1, DCTN2, VIP, IL18, PTK2, CDKSR1, FN1, KRT8, KRT18, PPARG, TGFBI, E2F1 | 3.88 |
| Cellular Assembly and Organization | APOH, PRKCD, SMAD3, TOP2A, CDH1, DCTN2, EBNA1BP2, NPPB, PTK2, CDKSR1, HCAP-D3, FN1, FGFR2, KRT8, KRT18, MARK2, LAMC1, PPARG, BNP3, E2F1 | 3.88 |
| Carbohydrate Metabolism | FN1, B4GALT5, NPPB, PTK2, IL18 | 3.11 |
| Cellular Movement | HOXB2, CCR9, C6, B4GALT5, SMAD3, PRKCD, MGLL, CDH1, LPS1, LAMAS, DCTN2, NPPB, CDKSR1, VIP, PTK2, IL18, FN1, BAG1, ITGAE, PPARG, TGFBI | 3.08 |
| Cellular Growth and Proliferation | SAT, PRKCD, TXNIP, SMAD3, CDH1, FTH1, LAMAS, SLC30A1, EBNA1BP2, VIP, IL18, PTK2, MLLT3, FGGF2, FN1, PLAC8, BAG1, PRKCC, BTG1, LAMC1, PPARG, BNP3, E2F1, SFRP4 | 3.05 |
| Cell Cycle | HCAP-D3, FN1, TXNIP, PRKCD, TOP2A, DCTN2, PPARG, EBNA1BP2, E2F1 | 2.57 |
| Molecular Transport | FGGF2, SAT, FN1, PRKCD, MGLL, BAG1, FTH1, PPARG, NPPB, PTK2, VIP, IL18 | 2.45 |
| Nucleic Acid Metabolism | SAT, BAG1, NPPB, VIP | 2.45 |
| Small Molecule Biochemistry | APOH, SAT, PRKCD, B4GALT5, MGLL, FTH1, ASAH1, NPPB, PTK2, IL18, VIP, ASS, GLRX, FGFR2, FN1, BAG1, GRPPARG | 2.45 |
| Cellular Function and Maintenance | CCR9, SMAD3, CDH1, SLC30A1, PTK2, IL18, CDKSR1, FN1, FGFR2, KRT8, ITGAE, PPARG, BNP3 | 2.25 |
| DNA Replication, Recombination, and Repair | HCAP-D3, FN1, SMAD3, PRKCD, TOP2A, FTH1, DCTN2, EBNA1BP2 | 2.17 |
| Gene Expression | APOH, SMAD3, PRKCD, CDH1, PKN2, VIP, IL18, FN1, BAG1, PRKCC, RNF4, PPARG, E2F1 | 2.13 |
| Cell Signaling | ASS, FN1, PRKCD, PPARG | 2.02 |
| Amino Acid Metabolism | ASS, FTH1 | 1.94 |
| Cellular Compromise | PRKCD, KRT18, TIMM8A, PPARG, E2F1 | 1.94 |
| Drug Metabolism | GLRX, FTH1, NPPB, IL18, VIP | 1.94 |
| Lipid Metabolism | FGFR2, APOH, SAT, FN1, MGLL, ASAH1, PPARG, NPPB, VIP | 1.94 |
| Post-Translational Modification | PRKCD, BAG1, PRKCC | 1.94 |
| Protein Folding | BAG1 | 1.94 |
| Protein Synthesis | BAG1, IL18 | 1.94 |
| Vitamin and Mineral Metabolism | FGFR2, FTH1, PPARG | 1.94 |
Taken together, these data suggest that EGC tend to shift IEC transcriptome toward an anti-proliferative phenotype. These results could lead to the identification of specific targets responsible for the anti proliferative effects of EGC previously reported [12]. In addition, this global effect is supported further by the observation that EGC inhibit cell proliferation in part by inducing a cell cycle arrest in G0/G1 phase [11].

*Cell survival*

EGC differentially regulated in IEC the expression of genes involved in cell death. EGC appeared to modulate the expression of anti-apoptotic and pro-apoptotic genes toward a dominant pro-apoptotic effect (Table 10).

Indeed, expressions of pro-apoptotic and anti-apoptotic genes were found to be up-regulated and down-regulated, respectively, by EGC. In particular, *BNIP3* and *CASP4* expression in IEC were up-regulated by EGC. *CASP4*, coding for the caspase-4 pro-apoptotic protein has been

| Ingenuity© Signalling Pathway | Genes | Ratio |
|--------------------------------|-------|-------|
| Circadian Rhythm Signaling     | VIP   | 0.046 |
| Cell Cycle: G1/S Checkpoint Regulation | SMAD3, E2F1 | 0.041 |
| Integrin Signaling             | ACTG2, FN1, LAMAS, LAMC1, PTK2 | 0.03  |
| Actin Cytoskeleton Signaling   | TMSB4Y, FGFR2, FN1, ITGAE, IQGAP2, PTK2 | 0.029 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | TOP2A | 0.029 |
| VEGF Signaling                 | ACTG2, PTK2 | 0.029 |
| Complement and Coagulation Cascades | FGG, C6 | 0.028 |
| Amyloid Processing             | CDKSR1 | 0.028 |
| ERK/MAPK Signaling             | PRKCD, PPAR, PTK2 | 0.024 |
| Wnt/β-catenin Signaling        | CDH1, MARK2, SFRP4 | 0.022 |
| FGF Signaling                  | FGFR2  | 0.018 |
| Chemokine Signaling            | PTK2   | 0.018 |
| TGF-β Signaling                | SMAD3  | 0.016 |
| Protein Ubiquitination Pathway | PSMC6, PSMC1, BAG1 | 0.016 |
| PPAR Signaling                 | PPAR   | 0.015 |
| IGF-I Signaling                | PTK2   | 0.015 |
| Apoptosis Signaling            | PRKCQ  | 0.015 |
| Neuregulin Signaling           | CDKSR1 | 0.015 |
| PTEN Signaling                 | PTK2   | 0.014 |
| Fc Epsilon RI Signaling        | PRKCD  | 0.014 |
| T Cell Receptor Signaling      | PRKCQ  | 0.014 |
| Xenobiotic Metabolism Signaling| PRKCD, PRKCQ | 0.010 |
| NF-κB Signaling                | PRKCQ  | 0.009 |
| B Cell Receptor Signaling      | PRKCQ  | 0.009 |
| Ephrin Receptor Signaling      | PTK2   | 0.009 |
| Leukocyte Extravasation Signaling | PTK2 | 0.008 |
| Huntington’s Disease Signaling | CDKSR1 | 0.007 |
| Axonal Guidance Signaling      | PTK2   | 0.004 |

| Table 6: Genes controlling intestinal epithelial cells adhesion and modulated by enteric glial cells. |

| Gene Symbol | Regulation of gene expression by EGC  | Gene Symbol | Regulation of gene expression by EGC  |
|-------------|--------------------------------------|-------------|--------------------------------------|
| CDH1        | up-regulated                         | CDKSR1      | down-regulated                       |
| IQGAP2      | up-regulated                         | KLK14       | down-regulated                       |
| LAMAS       | up-regulated                         |             |                                      |
| LAMC1       | up-regulated                         |             |                                      |
| FN1         | up-regulated                         |             |                                      |
| PTK2        | up-regulated                         |             |                                      |
| KRT8        | up-regulated                         |             |                                      |
shown to induce cell death [68,69], like BNIP3 which encodes a pro-apoptotic protein member of Bcl-2 family [70,71]. Conversely, ASAH-1, GPX2 and BAG-1 were down-regulated by EGC. BAG-1 encodes a known anti-apoptotic protein implicated in Bcl-2 signalling pathway [72,73]. ASAH-1 encodes acid ceramidase, an enzyme that catalyzes ceramide into sphingosine by deacylation. Overexpression of acid ceramidase in cells confers on them an increased resistance to cell death induced by various factors such as TNF (tumor necrosis factor) or anticancerous drugs [74,75]. Finally, GPX2 encodes a member of the glutathione peroxidase (GPX) family and is a selenoprotein and a glutathione peroxidase. GPX2 is expressed in IEC [76] and inhibits oxidative stress-induced apoptosis in the human breast adenocarcinoma cell line MCF-7 [77].

These global pro-apoptotic effects of EGC upon IEC have to be considered also in view of the EGC-mediated regulation of genes which would tend to be anti-apoptotic, although these are in reduced number. In particular, EGC up-regulated the expression of TUBB3, a gene encoding the class III isotype of β-tubulin. Silencing of class III β-tubulin by siRNA reverted anti-cancer agent-resistant cells to a sensitive phenotype and promoted apoptosis [78,79]. Conversely, EGC inhibited the expression of CARD12 which encodes the CARD12 protein, a member of the CED4/Apaf-1 family and known to induce apoptosis when expressed in cells [80,81].

EGC-induced regulation of genes involved in cell death has probably no clear consequences on IEC survival. This is consistent with a previous study showing that EGC did not modify IEC survival [12].

**Conclusion**

The present study described the impact of EGC upon the transcriptome of proliferating Caco-2 cells in a validated non-contact co-culture model of EGC and IEC [12,13]. The results obtained confirmed the known role of EGC in the control of some IEB functions and, more interestingly, extended their role in the control of novel major IEB and IEC functions. This study further reinforced the emerging concept that EGC are an important component of the IEB environment with major protective effects. Indeed, the major pathways regulated by EGC in IEC identified with microarrays lead to enhanced cell adhesion, differentia-

---

**Figure 4**

**Enteric glial cells (EGC) induced an increase in intestinal epithelial cells (IEC) adhesion.** (A): EGC induced a significant increase in IEC total adhesion (i.e. without discriminating cell-to-matrix and cell-to-cell adhesion) after 24 hours of co-culture in presence of EGC (+ EGC) as compared to control (- EGC) (n = 5; p = 0.008; Mann-Whitney test). (B): IEC were significantly more attached to their matrix when they were cultured for 24 hours with EGC (+ EGC) as compared to control (- EGC) (n = 13; p < 0.001; Mann-Whitney test).

---

**Table 7: Genes controlling intestinal epithelial cells differentiation and modulated by enteric glial cells.**

| Pro-differentiative | Anti-differentiative |
|--------------------|---------------------|
| **Gene Symbol**    | **Regulation of gene expression by EGC** | **Gene Symbol**    | **Regulation of gene expression by EGC** |
| CDH1               | up-regulated        | E2F1               | down-regulated      |
| PPARG              | up-regulated        | BAG1               | down-regulated      |
| LAMA5              | up-regulated        | CDK5R1             | down-regulated      |
| PTK2               | up-regulated        | FN1                | up-regulated        |
| DCTN2              | up-regulated        |                   |                     |
| DYNLT3             | up-regulated        |                   |                     |
tion, and motility, which could favor repair, and reduced cell proliferation.

An important result of this study is the putative identification of genes involved in the anti-proliferative effects of EGC. Indeed, EGC have been shown to have potent anti-proliferative effects upon IEC [11,12]. Interestingly, these effects were associated with an induction of a cell cycle blockade in the G0/G1 phase [11] but were not associated with significant cell death [12]. These results are globally confirmed, as there was no clear trend in the EGC-induced modulation of genes controlling cell survival in IEC but a trend toward an up-regulation of the expression of genes involved in anti-proliferative pathways.

A major finding of our study is that EGC regulated the expression of genes involved in cell adhesion and differentiation toward a global increase of IEC adhesive properties. These results can be analyzed in view of the known effects of EGC upon IEB. Indeed, *in vitro* studies have shown that EGC increase IEB resistance and decrease IEB paracellular permeability [13]. In the present study, we also demonstrated that EGC could increase global IEB adhesion, in part by increasing cell-to-matrix adhesion. These results are in agreement with *in vivo* data showing that selective lesions of EGC lead to increased paracellular permeability and major IEB breakdown associated with the development of intestinal inflammation. However, the role of the molecular actors involved in these processes such as fibronectin, laminin or cytokeratin remains to be investigated. EGC might also favor barrier integrity by increasing its resistance to inflammatory stress either by its ability to down-regulate inflammatory genes such as *CARD12* or by increasing IEC production of anti-inflammatory mediators such as VIP [82,83].

Another important finding of this study is the observation that EGC might regulate IEC metabolism. In particular, EGC up-regulated genes involved in lipid metabolism such as AADAC, MGLL or APOH, encoding respectively the arylacetamide deacetylase, monoglyceride lipase (MGL) and Apolipoprotein H [84-86]. Interestingly, inhibitors of MGL which is a serine hydrolase that converts 2-arachidonoylglycerol, a ligand of cannabinoid receptors, to fatty acids and glycerol, increased gut transit time [87] but its impact on IEB functions remain unknown. EGC also modulated the expression of genes involved in protein metabolism such as CTSH that encodes cathepsin H, a lysosomal cysteine protease [88]. In addition, EGC increased the expression of genes involved in arginine metabolic pathway that are SLC7A7 and ASS, which encode respectively for the cationic amino acid transporter γ(+)LAT1 and the arginosuccinate synthetase, enzyme catalyzing the penultimate step of the arginine biosynthetic pathways. The functional impact of EGC upon IEC metabolism needs to be investigated in future studies.

Regulation of IEB functions by EGC occurs mainly via paracrine pathways. The majority of EGC effects upon IEB functions are reproduced by glial-derived conditioned medium. In addition, various mediators have been identified as being involved in the control of cell proliferation or paracellular permeability. Our study supports the role of mediators such as TGF-β1 as a regulator of gene pathways modulated by EGC in IEC. In fact, TGF-β1 has been shown to increase the expression of FAK [43], TGFBI [89] or VIP [90]. EGC have also been shown to produce IL-6 [91]. IL-6 has recently been identified as a key molecule involved in IEB barrier protection via increasing both cytokeratin 8 and cytokeratin 18 proteins expression [92], whose mRNA expression were induced by EGC in IEC in

| Table 8: Genes controlling intestinal epithelial cells motility and modulated by enteric glial cells. |
|---------------------------------------------------------------|
| Gene Symbol | Pro-motility | Anti-motility |
| PPARG | up-regulated | down-regulated |
| FN1 | up-regulated | |
| PTK2 | up-regulated | |

| Table 9: Genes controlling intestinal epithelial cells proliferation and modulated by enteric glial cells. |
|---------------------------------------------------------------|
| Gene Symbol | Pro-proliferative | Anti-proliferative |
| E2F1 | down-regulated | up-regulated |
| FGFR2 | down-regulated | up-regulated |
| PPIL1 | down-regulated | up-regulated |
| MKI67 | up-regulated | |

| Gene Symbol | Regulation of gene expression by EGC | |
| TXNIP | up-regulated |
| BTG1 | |
| TPS3RK | |
| SFRP4 | |

| Regulation of gene expression by EGC | |
| up-regulated | up-regulated |
| up-regulated | up-regulated |
| down-regulated | down-regulated |

Page 14 of 20 (page number not for citation purposes)
our study. In this context, knowledge of genes modulated by EGC could direct future efforts aimed at identifying novel glial mediators involved in EGC control of IEB functions. Our data also further suggest that EGC differentially regulate some IEB functions as compared to fibroblasts, although comparison has only been performed on a limited set of genes and one cannot fully rule out that species differences could also be involved (fibroblasts of human origin vs. enteric glia of rat origin). However, these differences are consistent with the observation that while EGC have anti-proliferative effects on both human and rat IEC [12], fibroblasts increase IEC proliferation [93]. Collectively, our data support the concept that EGC play a key protective role upon IEB homeostasis by reinforcing global barrier functions. Additionally, our study reinforces data suggesting that enteric glia lesions and/or functional defects could be involved in the development of pathologies with altered barrier (such as inflammatory bowel diseases or colorectal cancer) and also be associated with increased barrier susceptibility to pathogen aggression.

Methods

Cell culture

CRL2690 (ATCC), a transformed EGC line isolated from adult rat myenteric plexus, was cultured in DMEM (4.5 g/L glucose; Gibco) supplemented with 10% heat-inactivated FBS, 2 mM glutamine (Gibco), 50 IU/mL penicillin and 50 μg/mL streptomycin. EGC were seeded at a concentration of 30,000 cells/mL in 6- and 12-well plates (Corning, Avon, France). EGC were cultured for an additional 24 hours after having reached confluence prior co-culture with IEC. CCD-18Co, a human colonic fibroblast cell line, was cultured in MEM Alpha Medium (Gibco) supplemented with 10% heat-inactivated FBS, 2 mM glutamine (Gibco), 0.1 mM MEM NEAA (Gibco), 50 IU/mL penicillin and 50 μg/mL streptomycin. Fibroblasts were seeded at a concentration of 130,000 cells/mL in 12-well plates (Corning). Fibroblasts were cultured in EGC medium, as described above, for an additional 24 hours after having reached confluence prior co-culture with IEC. Caco-2 cells (ATCC), isolated from a human colonic adenocarcinoma, were cultured in DMEM (4.5 g/L glucose; Gibco) supplemented with 10% heat-inactivated FBS, 2 mM glutamine (Gibco), 50 IU/mL penicillin and 50 μg/mL streptomycin and were seeded at a concentration of 140,000 cells/mL onto porous Transwell filters (6-well and 12-well Transwell clear, 0.40 μm porosity, Corning). Caco-2 cells were processed for experiment 1 day after their seeding. To characterize EGC impact onto IEC transcriptome and functions, IEC seeded onto filters were cultured in presence of EGC seeded at the bottom of the 6-well or 12-well plates.

Microarray experiments

Transcriptomic analysis was performed with a microarray of 6,864 genes called “Cancerochip” and available from the West Genopole transcriptome core facility of Nantes. These Cancerochips contained 6,864 probes (50-mer oligonucleotides), each specific of a single gene. These genes were selected to be preferentially and/or differentially expressed in Caco-2 cells and in various tumours. Three replicates of each probe were spotted onto Cancerochips. This allowed the measurement of the probes reproducibility within the array.

Total RNA was extracted from Caco-2 cells cultured on 6-well filters alone or in presence of EGC at t = 0, 8 and 24 hours. Each condition was performed in 4 replicates allowing the measurement of the reproducibility of the cell culture experiments. RNA extraction was performed with RNeasy mini kit (Qiagen) according to the manufacturer’s recommendations.

The protocols used for subsequent amplification and labelling were described in the DNA chips platform protocols. Each individual sample was compared to a reference pool consisting of Caco-2 cells transcripts of the four replicates extracted at t = 0 hour. Total RNA (0.5 μg) was amplified and labelled using the Amino Allyl MessageAmp II aRNA Amplification kit (Ambion) and CyDye Post Labelling Reactive Dyes (Amersham). After reverse transcription to synthesize first strand cDNA, second strand cDNA was subsequently synthesized following the manufacturer’s protocol. In vitro transcription was then achieved in order to amplify the initial transcripts quantity, concomitantly with aminoallyl-dUTP incorporation to perform labelling with cyanins (Cy5 for the reference and Cy3 for samples). The hybridization of the chips was
performed following the protocol of the West Genopole transcriptome core facility of Nantes. After washing, the chips were scanned (Scanexpress- Perkin Elmer).

Data analysis
After acquisition, the scanned images were analyzed using GenePix Pro v5.1 software (Axon). Raw signals were processed using the MADSCAN package http://cardioserve.nantes.inserm.fr/mad/madscan/. Spots with weak, saturated signal or badly shaped were considered as missing values. Print-tip lowess was applied to raw signals to normalize both channels (Cy3 and Cy5) of a same array. Fitting coefficients were calculated on rank invariant spots, assuming that they correspond to ubiquitous genes (genes that did not vary between samples). Sample to reference ratios (Cy3/Cy5) were further calculated, and Log transformed (Expression Logratios). Probes with more than 25% of missing values were rejected.

In order to identify differentially expressed genes, Expression Logratios were analyzed using Genespring v7.0 software (Agilent Technologies). Genes differentially expressed between Caco-2 cells cultured alone or in presence of EGC were searched with Benjamini and Hochberg False Discovery Rate method with a significance threshold of 0.05. This method includes a correction for multi-testing and has been widely used for microarray data [94]. This analysis led to the identification of 98 genes differentially expressed in IEC cultured in presence of EGC as compared to control, i.e. IEC cultured alone at t = 24 hours and none at t = 8 hours. Analysis of variance (ANOVA) using time of culture and presence/absence of EGC as parameters gave very similar results. Data visualization using hierarchical clustering and Volcano-Plot suggested that this strategy might have missed some differentially expressed genes at t = 24 hours; we thus selected an additional set of genes based on expression fold-changes. Twenty seven genes with a fold-change threshold of 2 and a t-test p-value < 0.05 without multi-testing correction were found. Altogether 116 unique genes were found differentially expressed in IEC at t = 24 hours of culture in presence of EGC as compared to control.

Hierarchical clustering was performed after normalization on medians of the ratio values of the t = 0 hour-condition samples. Hierarchical clustering was performed using the Cluster software. It was applied to order either genes and samples or genes only. It creates a visualization of the grouping of genes and samples based on profile similarity, even if it does not provide robustness assessment of the classification.

Among the 116 genes identified with Genespring analysis, 17 of them did not present reliable values at t = 0 hour. Thus, these 17 genes were excluded from hierarchical clustering analyses. As a consequence, clustering analyses only involved 99 genes.

Microarray data were uploaded to GEO database http://www.ncbi.nlm.nih.gov/geo/ and are available under the access number GSE17027.

RT-quantitative PCR
Extraction of total RNA from Caco-2 cells cultured alone, in presence of EGC or fibroblasts for 24 hours was performed with RNeasy Mini kit (Qiagen) according to the manufacturer's protocol. For reverse transcription, 1 μg of purified total RNA was denatured and subsequently processed for reverse transcription using SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer's recommendations. PCR amplifications were performed using the Absolute Blue SYBR green fluorescein kit (Abgene) according to the manufacturer's protocol and run on MyiQ thermocycler (Biorad). The expression of the gene S6 was analyzed in parallel as an internal control.

CDH1 [GenBank: NM_004360]
Forward primer:
5'-GACCAGGACTATGACTACTTGAACG-3'
Reverse primer:
5'-ATCTGCAAGGTGCTGGGTGAACCTT-3'

E2F1 [GenBank: NM_005225]
Forward primer:
5'-CCGCTCGAGGAGAAGTCACGCTATGA-3'
Reverse primer:
5'-CCCAAGCTTTTGGTGATGTCATAGATGC-3'

FN1 [GenBank: NM_054034]
Forward primer:
5'-GCAGGCTCAGCAAATGGTTCAG-3'
Reverse primer:
5'-AGGTAGGTCCGCTCCCACTG-3'

FGFR2 [GenBank: NM_022970]
Forward primer:
5'-GTCCCTGCCAAAACAGCAAG-3'
Reverse primer:
5'-CCCCTATGCAGTAAATGGCTA-3'
GPX2 [GenBank: NM_002083]
Forward primer:
5'-gtccttggcttcccttg-3'
Reverse primer:
5'-tgttcaggatctcctcattctg-3'
LAMA5 [GenBank: NM_005560]
Forward primer:
5'-CCCACCGAGGACCTTTACTGC-3'
Reverse primer:
5'-GGTGTGCCTTGTTGCTGTTGG-3'
PPARG [GenBank: NM_138712/NM_005037/
NM_138711/NM_015869]
Forward primer:
5'-ttgctgtcattattctcagtgga-3'
Reverse primer:
5'-gaggactcagggttgtcag-3'
PTK2 [GenBank: NM_153831/NM_005607]
Forward primer:
5'-GAGATCTGTCTCCAGTCTAC-3'
Reverse primer:
5'-TGCACCTGCTATTTTAGTTG-3'
SMAD3 [GenBank: NM 005902]
Forward primer:
5'-CCAAGCTTAGAACGGGACGGAGAG-3'
Reverse primer:
5'-CCTGCGGTTGGCTGCTGCGGAGG-3'
Reverse primer:
5'-CACTCGAGTGGCTGCTGCGAGGTC-3'
S6 [GenBank: NM_001010]
Forward primer:
5'-TGCAAGATGATCCCAATGAG-3'
Reverse primer:
5'-AGCCITCCTTGGGGACACCTGCT-3'

Adhesion experiments

Global adhesion assay
IEC adhesion was estimated by performing a "global adhesion assay" that evaluated total IEC adhesion to their environment, i.e. adhesion to neighboring IEC and adhesion to matrix. IEC were cultivated on filters (12-well Transwell clear, 0.40 μm porosity, Corning) alone or in the presence of EGC for 24 hours. IEC were then trypsinized with 0.01% trypsin-EDTA free (Sigma) allowing gentle trypsinization for 30 minutes at 37°C. Non-adherent IEC were harvested and counted in a blind fashion using Malassez slides (VWR international). IEC remaining adhered on filters were trypsinized with 2.5% trypsin with EDTA (Gibco), harvested and counted. Results are expressed in percentage of remaining adherent IEC normalized to the total number of counted IEC (i.e., adherent IEC and non-adherent IEC). Only those series in which the percentage of IEC total adhesion in control condition was comprised between 20 and 70% were analyzed.

Cell-to-matrix adhesion assay
IEC were cultivated on filters (12-well Transwell clear, 0.40 μm porosity, Corning) alone or in presence of EGC for 24 hours. IEC were then trypsinized for 10 minutes with a 2.5% trypsin-EDTA (Gibco). Trypsin was neutralized with IEC culture medium (see above). IEC were subsequently reseeded on filters and incubated for 3 hours at 37°C. Time of incubation has been defined to allow 50% of seeded IEC to adhere to filters in control condition. Following incubation, unseeded cells were harvested and counted in a blind fashion using Malassez slides (VWR international). IEC that had adhered on filters were trypsinized and counted. Results are expressed in percentage of adherent IEC normalized to the total number of counted IEC (i.e., adherent IEC and non-adherent IEC). Only those series in which the percentage of IEC total adhesion in control condition was comprised between 20 and 70% were analyzed.

List of abbreviations
CNS: Central nervous system; EGC: Enteric glial cells;
ENS: Enteric nervous system; FAK: Focal adhesion kinase;
IEB: Intestinal epithelial barrier; IEC: Intestinal epithelial cells; PPARγ: Peroxisome proliferator-activated receptor gamma; TGF-β1: Transforming growth factor beta-1; VIP: Vasoactive intestinal peptide.

Authors' contributions
LVL designed microarrays studies and carried out functional experiments and carried out microarrays studies. She analyzed the microarrays data and wrote the manuscript. MMM designed and carried out functional experiments and performed RT-qPCR studies. JL supervised microarray studies. IG participated in microarrays hybridization. RT assisted with the bioinformatics analysis. RH contributed to the bioinformatics analysis and wrote the manuscript. MN supervised the project and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors are grateful to Dr. Damien MASSON for kindly giving PPARγ primers. They also thank the West Genopole transcription core facility for providing expertise and technical help. They thank Philippe Aubert for his technical assistance. The authors are thankful to Anne Tomasevich for her help in editing the paper. LVL was supported by a PhD grant of the MNRT and MMM by a PhD grant from Nantes Métropole. This work was supported by a grant from INCa Appel d’Offre Libre 2007 (MOPRESTAGLIA).

References
1. Powell DW, Adgeboyega PA, Di Mari JF, Mifflin RC: Epithelial cells and their neighbours I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 2005, 289(1):G2-7.
2. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB: Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999, 277(2 Pt 1):C183-201.
3. Bilklsager AT, Moeser AJ, Gookin JL, Jones SL, Odle J: Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007, 87(2):545-564.
4. Mifflin RC, Powell DW, Shang H: Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res 2006, 66(7):846-855.
5. Penna FJ, Peret LA, Vieira LQ, Nicoli JR: Probiotics and mucosal barrier in children. Curr Opin Clin Nutr Metab Care 2008, 11(5):640-644.
6. Toumi F, Neunlist M, Cassagnau E, Parois S, Laboisse CL, Galmiche JP, Jarry A: Human submucosal neurons regulate intestinal epithelial cell proliferation: evidence from a novel co-culture model. Neurogastroenterol Motil 2003, 15(3):239-242.
7. Xue J, Askwith C, Javed NH, Cooke HJ: Autonomic nervous system and secretion across the intestinal mucosal surface. Auton Neurosci 2007, 133(1):55-63.
8. Neunlist M, Toumi F, Oreschkova T, Denis M, Leborgne J, Laboisse CL, Galmiche JP, Jarry A: Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003, 285(5):G1028-1036.
9. Ruhl A: Gial cells in the gut. Neurogastroenterol Motil 2005, 17(6):771-780.
10. Savidge TC, Sofroniew MV, Neunlist M: Starring roles for astroglia in barrier pathologies of gut and brain. Lab Invest 2007, 87(6):731-736.
11. Neunlist M, Van Landeghem L, Bourrelle A, Savidge T: Neuro-glial crosstalk in inflammatory bowel disease. J Intern Med 2008, 263(6):577-583.
12. Neunlist M, Aubert P, Bonnaud S, Van Landeghem L, Consen E, Wedel T, Naveilhan P, Ruhl A, Lardeux B, Savidge T, et al.: Enteric glia inhibit intestinal epithelial cell proliferation partly through a TGF-beta1-dependent pathway. Am J Physiol Gastrointest Liver Physiol 2007, 292(1):G231-241.
13. Savidge TC, Newman MA, Bakulakis C, Ruhl A, Neunlist M, Bourrelle A, Hurst R, Sofroniew MV: Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosothiol. Gastroenterology 2007, 132(4):1344-1358.
14. Bush TG, Savidge TC, Freeman T, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV: Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998, 93(2):189-201.
15. Aube AC, Cabarracas J, Bover J, Philippe D, Aubert P, Doulay F, Liblau R, Galmiche JP, Neunlist M: Changes in enteric neuropho-2011 type and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut 2006, 55(3):630-637.
16. Escaffi F, Perreault N, Jean D, Francon E, Rancourt C, Rival N, Vachon PH, Pare F, Boucher MP, et al.: Repressed E-cadherin expression in the lower crypt of human small intestine: a marker of functional relevance. Exp Cell Res 2005, 302(2):206-220.
17. Pecina-Slaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003, 3(1):17.
18. Lin S, Wang J, Ye Z, Ip NY, Lin SC: CDK5 activator p35 downregulates E-cadherin protein level independently of CDK5. FEBS Lett 2008, 582(8):1197-1202.
19. Briggs MW, Sacks DB: IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep 2003, 4(6):571-574.
20. Natale DR, Watson AJ: Rac-1 and IQGAP are potential regulators of E-cadherin-catenin interactions during murine preimplantation development. Gene Exp Patterns 2002, 2(1-2):17-22.
21. Tsu J, Marinkovich MP: Bridging structure with function: structural, regulatory, and developmental role of laminins. Int J Biochem Cell Biol 2008, 40(2):199-214.
22. Turck N, Gross I, Gendry P, Stutzmann J, Freund JN, Kedinger M, Simon-Assmann P, Launay JF: Laminin isoforms: biological roles and effects on the intracellular distribution of nuclear proteins in intestinal epithelial cells. Exp Cell Res 2005, 303(2):494-503.
23. Kolachala VL, Bajaj R, Wang L, Yao Y, Ritzenthaler JD, Gewirtz AT, Roman J, Merlin D, Staraman SV: Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation. J Biol Chem 2007, 282(45):32955-32964.
24. Borgono CA, Michael IP, Shaw J, Luo LY, Ghosh MC, Soosapillai A, Grass L, Katsaros D, Diamandis EP: Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Bio Chem 2007, 282(4):2405-2422.
25. Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6(1):56-68.
26. Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, Xiong D: Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 2008, 10(1):1275-1284.
27. Chen L, Bush CR, Necela BM, Su W, Yangasigawa M, Anastasiadis PZ, Fields AP, Thompson EA: RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in non-transformed intestinal epithelial cells. Mol Cell Endocrinol 2006, 251(1-2):17-32.
28. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrory C, Colombel JF, Najib J, Frucht JC, Datz C, Vidal H, et al.: Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999, 162(3):331-340.
29. Mahoney ZK, Stappenbeck TS, Miner JH: P2X7 receptor function and inflammation via release of S-nitrosoglutathione. Gastroenterology 2006, 1344-1358.
30. Levy P, Robin H, Knorpos M, Cappi A, Cherqui G: Enteroendocrine differentiation of the human Caco-2 cell line correlates with alterations in integrin signaling. J Cell Physiol 1998, 177(4):618-627.
31. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251(5006):1451-1455.
32. Laprise P, Chailier P, Houde M, Besuelle JF, Boucher MJ, Rivard N: Phosphatidylinositol 3-kinase controls human intestinal epithelial cell differentiation by promoting adherens junction assembly and p38 MAPK activation. J Biol Chem 2002, 277(10):8226-8234.
BMC Genomics 2009, 10:507
http://www.biomedcentral.com/1471-2164/10/507

33. Ku NO, Zhou X, Toivola DM, Omary MB: The cytoskeleton of digestive epithelia in health and disease. Am J Physiol 1999, 277(6 Pt 1):H208-137.
34. Fath KR, Tsigmon GB, Purgess DR: Molecular motors are differentially distributed on Golgi membranes from polarized epithelial cells. J Cell Biol 1994, 126(3):661-675.
35. Tai AW, Chung JH, Sung CH: Cytoplasmic dynein regulation by subunit heterogeneity and its role in apical transport. J Cell Biol 2001, 153(7):1499-1509.
36. Vachon PH, Simoneau A, Herringer-Gillam FE, Beaulieu JJ: Cellular fibronectin expression is down-regulated at the mRNA level in differentiating human intestinal epithelial cells. Exp Cell Res 1995, 216(1):30-34.
37. Deschenes C, Alvarez L, Lizotte ME, Veza M, Rivard N: The nuclear-octoplasmonic shuttling of ETF4E is involved in the regulation of human intestinal epithelial cell proliferation and differentiation. J Cell Physiol 2004, 199(2):262-273.
38. Howarth TH, Cardin E, Harrois C, Reed JC, Veza M: Early establishment of epithelial apoptosis in the developing human small intestine. Int J Dev Biol 2000, 44(8):891-898.
39. Leeb SN, Vogl D, Grossmann J, Falk W, Scholmerich J, Rogler G, Gelbmann CM: Autocrine fibronectin-induced migration of human colonic fibroblasts. Am J Gastroenterol 2004, 99(2):335-340.
40. Goke M, Zuk A, Podolsky DK: Regulation and function of extracellular matrix intestinal epithelial restitution in vitro. Am J Physiol 1996, 271(5 Pt 1):G729-740.
41. Hines OJ, Ryder N, Chu J, McFadden D: Lysophosphatidic acid stimulates intestinal restitution via cytoskeletal activation and remodeling. J Surg Res 2000, 92(1):23-28.
42. Walah MF, Ampasala DR, Hatfield J, Heide R, Vander S, Rishi AK, Basson MD: Transforming growth factor-beta stimulates intestinal epithelial focal adhesion kinase synthesis via Smad and p38-dependent mechanisms. Am J Pathol 2008, 173(2):385-399.
43. Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, Ikeda I, Hosono K, Endo H, Oneda K, Iida H, et al.: Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci 2008, 99(10):1892-1900.
44. Kim KR, Choi HW, Lee HJ, Baek HA, Park HS, Jang KY, Chung MJ, Moon WS, Takahashi H, Chiba T: TNF-α and p38-dependent mechanisms, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal cancer cells. Int J Cancer 2007, 120(3):702-713.
45. Fujisawa T, Nakajima A, Fujisawa N, Takahashi H, Ikeda I, Tomimoto A, Yonemitsu K, Nakajima N, Kudo C, Wada K, et al.: Peroxisome proliferator-activated receptor gamma (PPARγ) reduces tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle inhibition and suppression of radiation-induced apoptosis in human renal carcinoma cells. Cancer Sci 2006, 97(12):1710-1717.
46. Abe Y, Takeuchi T, Imai Y, Murasue R, Komai Fujibuchi T, Matsumoto S, Ueda N, Ogasawara M, Shigemoto K, Hitsuimoto Y, Nikawa J, et al.: Cloning and characterization of a p53-related protein kinase expressed in inter-leukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. J Biol Chem 2001, 276(47):44003-44011.
47. Abe Y, Takeuchi T, Komai Fujibuchi T, Matsumoto S, Ueda N, Ogasawara M, Shigemoto K, et al.: A Small RAS-like protein Rafliploc3 modulates the p53-regulating activity of PRPK. Biochem Biophys Res Commun 2006, 344(1):353-357.
48. Harvath LG, Henshall SM, Kench JG, Saunders DN, Lee CS, Golovsky D, Bremer PC, O'Neill GF, Koerner R, Stricker PD, et al.: Membrane expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res 2004, 10(2):615-625.
49. Carmon KS, Loose DS: Secreted frizzled-related protein 4 regulates wound healing and inhibits proliferation of endometrial cancer cells. Mol Cancer Res 2008, 6(6):1017-1028.
50. Lin R, Sun Y, Li C, Xie C, Wang S: Identification of differentially expressed genes in human lymphoblastoid cells exposed to irradiation and suppression of radiation-induced apoptosis with antisense oligonucleotides against caspase-4. Oligonucleotides 2007, 17(3):314-326.
51. Martin CA, Panja A: Cytokine regulation of human intestinal primary epithelial cell susceptibility to Fas-mediated apoptosis. Am J Physiol Gastrointest Liver Physiol 2002, 282(1):G92-G104.
52. Ray R, Chen G, Velde C, Vande C, Cizaew J, Park JH, Reed J, Gietz RD, Greenberg AH: BNIP3 heterodimers with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3
(BH3) domain at both mitochondrial and nonmitochondrial sites. J Biol Chem 2000, 275(2):1439-1448.

71. Chew-Weyer CL, Payne CM, Glassman GM, Watzs GS, Futscher B, Walneire CN, Crowley C, Dvorakova K, Bernstein C, Cranen M, et al.: Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxoycholate. Carcinogenesis 2002, 23(12):2063-2080.

72. Tang SC. BAG-1, an anti-apoptotic tumour marker. IUBMB Life 2002, 53(2):99-105.

73. Clemo NK, Arhel NJ, Barnes JD, Baker J, Moorghen M, Packham GK, Parakeva C, Williams AC: The role of the retinoblastoma protein (Rb) in the nuclear localization of BAG-1: implications for colorectal tumour cell survival. Biochim Soc Trans 2005, 33(Pt 6):676-678.

74. Saad AF, Meacham WD, Bai A, Anelli V, Eloeijemy S, Mahdy AE, Turner LS, Cheng J, Bielawiska A, Bielawski J, et al.: The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007, 6(9):1455-1460.

75. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, Adam D: Overexpression of acid ceramidase protects from tumour necrosis factor-induced cell death. J Exp Med 2000, 192(5):601-612.

76. Florian S, Wingler K, Schmelk H, Jacobasch G, Kreuzer OJ, Meyerhof W, Brigelius-Flohe R: Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue. Free Radic Res 2001, 35(6):655-663.

77. Yan W, Chen X: GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem 2006, 281(12):7856-7862.

78. Mhaidat NM, Thorne RF, de Bock CE, Zhang XD, Hersey P: Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Lett 2008, 582(2):267-272.

79. Kavallaris M, Burkhart CA, Horwitz SB: Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999, 80(7):1020-1025.

80. Geddes BJ, Wang L, Huang WJ, Lavellee M, Manji GA, Brown M, Jurman M, Cao J, Morgenstern J, Merriam SM, et al.: Human CARD12 is a novel CED4/Ipafs family member that induces apoptosis. Biochem Biophys Res Commun 2001, 284(1):77-82.

81. Lu C, Wang A, Wang L, Dorsch M, Ocan TD, Xu Y: Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation. Biochem Biophys Res Commun 2005, 331(4):114-119.

82. Gonzalez-Rey E, Delgado M: Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr Opin Investig Drugs 2005, 6(11):1161-1123.

83. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WJP, Roos-Geirna M, Erickson S, Dixit VM: Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004, 430(6996):213-218.

84. Trickett JL, Patel DD, Knight BL, Saggerson ED, Gibbons GF, Pease RJ: Characterization of the rodent genes for arylacetamide deacetylase, a putative microsomal lipase, and evidence for transcriptional regulation. J Biol Chem 2001, 276(43):39522-39532.

85. Nakaya Y, Schaefer E, Brewer HB Jr: Activation of human postheparin lipoprotein lipase by apolipoprotein H (beta-2-glycoprotein I). Biochem Biophys Res Commun 1980, 95(3):1168-1172.

86. Ho SY, Delgado L, Storch J: Monoacylglycerol metabolism in human intestinal Caco-2 cells: evidence for metabolic compartmentation and hydrolysis. J Biol Chem 2002, 277(18):1816-1823.

87. Duncan M, Thomas AD, Cluny NL, Patel A, Patel KD, Lutz B, Piomelli D, Alexander SP, Sharkey KA: Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2008, 295(6):G1255-G1265.

88. Bolhey P, Soglen PO: Proteases and proteolysis in the lysosome. Experientia 1992, 48(2):151-157.

89. Thapa N, Lee BH, Kim IS: TGFBlp/betag-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol 2007, 39(12):2183-2194.

90. Pitts RL, Wang S, Jones EA, Symes AJ: Transforming growth factor-beta and ciliary neurotrophic factor synergistically induce vasoactive intestinal peptide gene expression through the cooperation of Smad, STAT, and AP-I sites. J Biol Chem 2001, 276(23):19966-19973.

91. Ruhl A, Franzeke S, Collins SM, Stremmel W: Interleukin-6 expression and regulation in rat enteric glial cells. Am J Physiol Gastrointest Liver Physiol 2001, 280(6):G1163-G1171.

92. Wang L, Srinivasan S, Theiss AL, Merlin D, Staraman SV: Interleukin-6 induces keratin expression in intestinal epithelial cells: potential role of keratin-8 in interleukin-6-induced barrier function alterations. J Biol Chem 2007, 282(11):8219-8227.

93. Goke M, Kanai M, Podolsky DK: Intestinal fibroblasts regulate intestinal epithelial cell proliferation via hepatocyte growth factor. Am J Physiol 2001, 272(4 Pt 1):G809-G818.

94. Efron B, Tibshirani R: Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol 2002, 23(1):70-86.